Heterotopic ossification of muscles, tendons and ligaments are a common problem affecting patient with trauma or received elective surgery. But the existing preventive or therapeutic methods all have disadvantages. Runt-related protein 2 (Runx2) and Smad4 are two regulators that have important roles in the differentiation of osteoblast. In this study, we attempted to examine the effect of Runx2 and Smad4 on the development of heterotopic ossification in vitro. We constructed non-virus-containing small interference RNAs (siRNAs) against Runx2 and Smad4 and tested it with reverse transcriptase-PCR and western blot. We then analyzed the independent effect of Runx2-and Smad4-specific siRNAs and their cooperative effect on the formation of heterotopic ossification induced by trauma in rats. The effects were measured with computed tomography scanning, hematoxylin and eosin staining and immunohistochemistry. We found that the Runx2-and Smad4-specific siRNAs inhibited the expression of Runx2 and Smad4 at the level of messenger RNA and protein. Runx2 and Smad4 independently inhibited the formation of heterotopic ossification. Moreover, their co-expression significantly enhanced the inhibition of heterotopic ossification compared with the independent effect. We suggest that gene therapy to inhibit Runx2 and Smad4 by RNAi could be a powerful approach to prevent or treat heterotopic ossification.
Introduction
Heterotopic ossification is defined as the formation of bone outside the skeletal system. Loss of joint mobility and resulting loss of function are the principal complication of heterotopic ossification. [1] [2] [3] The heterotopic ossification of muscles, tendons and ligaments can be a problem after musculoskeletal trauma, severe burns, neurologic injury, elective surgery and fibrodysplasia ossificans progressiva. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] X-ray image revealed an incidence of 15-90% of heterotopic ossification in patients who received total hip arthroplasty in spite of preventive radiotherapy, with 1-27% of the patients reporting clinically important pain and loss of motion. 15 The incidence of burn-associated heterotopic ossification ranges between 1 and 3%, but can be as high as 35% for larger, more severe burns. 12, 16, 17 In patients with spinal cord injury, heterotopic ossification was reported to appear in 16-53% of patients, one-third of whom had clinically important manifestations. 18, 19 Besides, heterotopic ossification was also reported in non-skeletal tissues such as the gastrointestinal tract. 20 The exact etiology of heterotopic ossification remains unclear. However, researches suggest that the overexpression of certain bone morphogenetic proteins (BMPs) belonging to the tumor growth factor (TGF)-b super family might have a role in heterotopic ossification. 21 Another factor TGF-b is an important physiological regulator of osteoblast function and differentiation during bone formation. Wild burger R reported that growth hormone, prolactin, insulin-like growth factor type I and basic fibroblast growth factor were implicated in the formation of heterotopic ossification after head injury. 22, 23 It is likely that a complex and poorly understood interaction between a wide variety of stimulating factors and primary osteoblasts is involved in the formation heterotopic ossification.
During osteoblast differentiation, a set of bone-specific genes are activated. [24] [25] [26] [27] [28] [29] Runt-related protein 2 (Runx2) is a key regulator of osteocalcin and alkaline phosphatase gene promoters and cooperates with BMP-specific Smads. 24 Smads are primary cytoplasmic signal transducers of BMPs and TGF-b. Smad4 is the common mediator shared by signaling pathways for BMPs and TGF-b. 25 Therefore, Runx2 and Smad4 may be master regulators in osteoblast differentiation. [26] [27] [28] [29] Currently, there is no effective preventive or therapeutic method for heterotopic ossification of trauma. Therefore, it is important to examine a new method of treatment. Lin et al. 30 reported that adenovirus-mediated transfer of small interference RNA (siRNA) against Runx2 partially inhibits the formation of heterotopic ossification in mice. Less heterotopic ossification was observed in the treated limbs with 90% reduction. In this study, we designed recombinant non-viral vectors encoding siRNAs against Runx2 and Smad4, and analyzed their effects on Runx2 and Smad4 expression and osteoblast differentiation in cultured osteoblastic cells. The vectors were also tested against an established trauma model of heterotopic ossification. 31 
Results
Transfect ion with siRNAs against Runx2 and Smad4 strongly suppressed Runx2 and Smad4 expression in primary osteoblastic cells
Reverse transcriptase-PCR (RT-PCR) and western blot analysis revealed that siRNA 1057-1077 led to remarkable suppression of Runx2 expression compared with the other Runx2 siRNAs (Figure 1) , and that siRNA 139-159 led to remarkable suppression of Smad4 expression compared with the other Smad4 siRNAs (Figure 2 ). No change was observed using the scrambled siRNA at different concentrations (data not shown). Thus, in primary osteoblastic cells, siRNA exerted a powerful and specific knockdown effect on Runx2 expression and siRNA 139À159 exerted a powerful and specific knockdown effect on Smad4 expression. Therefore, we decided to choose the target sites of siRNA and siRNA 139À159 as the target sites for non-viral siRNA treatment.
Non-virus-mediated transduction of siRNAs against Runx2 and Smad4 suppressed Runx2 and Smad4 expression in primary osteoblasts
Reverse transcriptase-PCR and western blotting showed that the silencing effects of siRNAs against Runx2 and Smad4 were transient (data not shown). Thus, we constructed recombinant non-virus vectors encoding siRNAs targeting Runx2 and Smad4 and tested the effect of the encoded siRNAs on Runx2 and Smad4 expression respectively in primary osteoblasts. The target site of PiggyBac (PB)-Runx2-siRNA was the same as siR-NA . The target site of PB-Smad4-siRNA was the same as siRNA . RT-PCR and western blot analysis revealed that PB-Runx2-siRNA led to remarkable and persistent suppression of Runx2 expression over 14 days, whereas no change was observed after pcDNA4/HisA (control) transfect ion ( Figure 3 ). Similarly, PB-Smad4-siRNA led to remarkable and persistent suppression of Smad4 expression over 14 days (Figure 4 ). These results indicated that non-virus-mediated transduction of siRNA into primary osteoblastic cells was feasible.
Non-virus-mediated transduction of siRNAs against Runx2 and Smad4 inhibited osteoblast differentiation in primary osteoblasts
To further confirm the effects of PB-Runx2-siRNA and PB-Smad4-siRNA on osteoblast differentiation, the expression messenger RNA for an osteoblast phenotypic marker in primary osteoblasts was detected by RT-PCR. The expression of osteocalcin was clearly downregulated (Figure 5a ). Osteoblast terminal differentiation was determined by von kossa staining and the results showed that mineralization were significantly 
Animal experiments
We evaluated the ability of non-viral transduction of siRNA against Runx2 to inhibit heterotopic ossification after Achilles tenotomy. Ten weeks after surgery, the eight rats showed computed tomography (CT) evidence of heterotopic ossification formation in limbs not treated with siRNA. The treated limbs showed significantly less heterotopic ossification formation (Pp0.05), with a 93% reduction (Table 1) . Furthermore, two of the eight rats had no CT evidence of heterotopic ossification in the limbs treated with 100 mg PB-Runx2-siRNA. The representative three-dimensional CT scans, the hematoxylin and eosin staining and the immunohistochemistry examinations showed the effect of siRNA non-viral vectors against Runx2 on heterotopic ossification formation in rats ( Figure 6 ). Similarly, we evaluated the ability of non-viral transduction of siRNA against Smad4 to inhibit heterotopic ossification after Achilles tenotomy. Ten weeks after surgery, the eight rats showed CT evidence of heterotopic ossification formation in limbs not treated with siRNA. The treated limbs showed significantly less heterotopic ossification formation (Pp0.05), with a 92% reduction (Table 1) . Furthermore, two of the eight rats had no CT evidence of heterotopic ossification in the limbs treated with 100 mg PB-Smad4-siRNA. The representative threedimensional CT scans, the hematoxylin and eosin staining and the immunohistochemistry examinations showed the effect of siRNA non-viral vectors against Smad4 on heterotopic ossification formation in rats ( Figure 7 ).
We evaluated of the ability of non-viral transduction of siRNA against both Runx2 and Smad4 to inhibit heterotopic ossification after Achilles tenotomy. Ten weeks after surgery, the eight rats showed CT evidence of heterotopic ossification formation in untreated limbs. The treated limbs showed significantly less heterotopic ossification formation (Pp0.05), with a 97% reduction (Table 1) . Furthermore, six of the eight rats had no CT evidence of heterotopic ossification in the limbs treated with 100 mg PB-Runx2-siRNA and 100 mg PB-Smad4-siRNA. The representative three-dimensional CT scans, the hematoxylin and eosin staining and the immunohistochemistry examinations showed the effect of siRNA non-viral vectors against both Runx2 and Smad4 on heterotopic ossification formation in rats ( Figure 8 ). However, the reduction of heterotopic ossification volume was significantly greater than that of group Runx2 and group Smad4 (Pp0.05).
Discussion
Runt-related protein 2 and Smad4 may be master regulators in osteoblast differentiation. We attempted to inhibit the expressions of Runx2 and Smad4 to examine a new approach to gene therapy for heterotopic ossification. The terminal differentiation was determined by von kossa staining. The results showed that mineralization was significantly suppressed in the presence of siRNA non-viral vectors against Runx2 or Smad4 on day 21, whereas mineralization was completely suppressed in the presence of siRNA non-viral vectors against Runx2+Smad4 on day 21.
Non-virus-mediated transfer of siRNAs T Xue et al
It is presumed that pluripotential mesenchymal cells differentiate into osteoblasts under the influence of several growth factors, leading to heterotopic ossification. 32 Runx2 is a runt-related transcription factor that is essential for osteoblast differentiation and regulates the expression of osteoblastic genes, including type I collagen, osteopontin, bone sialoprotein and osteocalcin gene. [26] [27] [28] [29] Reduction in its level of expression would be predicted to inhibit the osteogenic potential of an osteoblastic cell line. Furthermore, Ducy et al. 33 and Banerjee et al. 34 showed that disruption of Runx2 by antisense oligonucleotides in osteoblast cultures inhibits the expression of osteoblast differentiation markers and the formation of mineralized nodules. Smad4 is the common mediator Smad shared by signaling pathways for BMPs and TGF-b. 25 As a common mediator Smad of TGF-b signaling, Smad4 is expressed in osteoblasts and mediates the effects of both BMP and TGF-b signals in cultured human osteoblasts. 35 Several in vitro studies suggest that Smad4 has an important role in osteoblasts by interacting with other molecules, such as Runx2 and Fos. 36, 37 Tan et al. 26 showed that Smad4 mutant mice showed low bone mass. The proliferation and function of the mutant osteoblasts were decreased. We synthesized Runx2-and Smad4-specific siRNAs by in vitro transcription, screened for efficacious siRNAs, constructed nonviral siRNA vectors, and used them in the subsequent experiments.
We constructed non-viral siRNA vectors, and used them in gene therapy heterotopic ossification. For the therapeutic application of siRNA technology, it might be critical to use an efficient gene delivery system for transduction of siRNA into target cells. Usually, a vectorexpressed short hairpin RNA works significantly longer than chemically synthesized siRNA. Plasmids equipped with a resistance gene can be used to select transfected cell lines in which the target gene can be downregulated for several months. 38 The use of non-viral vectors is considered to be a powerful tool in gene therapy because they have been shown to transducer genes efficiently into many types of cells.
We showed that non-virally transduced siRNAs against Runx2 and Smad4 exerted a powerful effect on osteoblast differentiation in vitro. We examined Runx2 and Smad4 messenger RNA levels by RT-PCR and protein levels by western blotting, and showed that the expressions of Runx2 and Smad4 were significantly downregulated in PB-Runx2-siRNA and PB-Smad4-siRNA transfected cells. These data suggested that the non-viral Runx2-specific and Smad4-specific siRNA were expressed in primary osteoblasts and silenced the expression of the genes. The inhibition of Runx2 or Smad4 expression by RNAi precluded the expected onset of osteoblast gene expression (osteocalcin). The terminal differentiation of osteoblast was also inhibited, as shown by von kossa assays ( Figure 5 ). These changes indicated that osteoblast differentiation was arrested because of the downregulation of Runx2 or Smad4 gene expression. Thus, siRNA could have an important role as a therapeutic application for heterotopic ossification.
In animal experiments, our research showed that inhibition of Runx2 and Smad4 could inhibit the formation of heterotopic ossification induced by Achilles tenotomy; co-expression could significantly enhance the inhibiting effect on heterotopic ossification. We found that Runx2-specific siRNA can partially inhibit the formation of heterotopic ossification induced by trauma. Our results showed that Runx2-specific siRNA is capable of inhibiting the formation of heterotopic ossification induced by Achilles tenotomy, further confirming that Runx2 is a master regulator of osteoblast differentiation and a molecular switch in osteoblast biology. [26] [27] [28] [29] The Smad4-specific siRNA is capable of partially inhibiting the formation of heterotopic ossification induced by Achilles tenotomy, providing evidence for that TGF-b might have a role in the formation of heterotopic ossification induced by Achilles tenotomy. Animal experiments showed that Runx2-or Smad4-specific siRNA could inhibit heterotopic ossification by approximately 92%, but could not completely inhibit heterotopic ossification. And the co-expression of Runx2-and Smad4-specific siRNA was capable of inhibiting the formation of heterotopic ossification by approximately 97%. We found that both these siRNA plasmids can partially inhibit heterotopic ossification and that the combination of both is better than either one alone.
Current methods for preventing or treating heterotopic ossification of trauma all have associated disadvantages. The effective treatment for heterotopic ossification is surgical resection. However, homeostasis might increase the risk of recurrence heterotopic ossification. Radiation therapy carries a secondary malignant risk, even with doses as small as 1000 cGy, and can also be associated with patient morbidity after total hip arthroplasty. 39, 40 In addition, radiation damages cells, including muscle cells, and thereby impairs healing. 41, 42 Non-steroidal anti-inflammatory drugs have been shown to prevent heterotopic ossification, but they can also cause considerable gastrointestinal bleeding. 43 More importantly, they systemically inhibit all bone-healing, which may be detrimental when trying to promote bonehealing elsewhere in the body. 44 Therefore, it is essential that indirect gene therapy might offer a method to accurately deliver Runx2 and Smad4 siRNAs to a targeted area of the body and thereby inhibit heterotopic ossification without interfering with bone-healing and bone growth at other locations. Further, alkaline phosphatase has been recommended as a useful screening tool for heterotopic ossification. Alkaline phosphatase levels become abnormal approximately 14 day after injury. In the typical case of heterotopic ossification, the alkaline phosphatase levels reached 3.5 times the normal value after the inciting trauma. Orzel and Rudd Non-virus-mediated transfer of siRNAs T Xue et al recommended starting drugs as soon as elevated alkaline phosphatase is noted. Lin et al. 30 reported that alkaline phosphatase activity increased and cells progressed through differentiation in mouse cells on the day 14. However, this increase was blocked by Ad-Runx2-siRNA treatment. We showed that non-virally transduced siRNAs against Runx2 and Smad4 exerted a powerful effect on osteoblast differentiation in vitro on the day 14. So we recommended that such treatment should start after day 14.
45
In conclusion, Runx2 and Smad4 are essential for osteoblast differentiation and non-virus-mediated transfer of siRNA against Runx2 and Smad4 can inhibit heterotopic ossification induced by trauma in rats. Although the precise mechanism of siRNA remains to be determined, it is likely that Runx2 and Smad4 siRNAs could be developed as a powerful approach to prevent or treat heterotopic ossification.
Materials and methods
We cultured primary osteoblasts, and chose six target sequences for rat Runx2 and Smad4 messenger RNA and 
Non-virus-mediated transfer of siRNAs
T Xue et al constructed non-virus siRNA plasmid. Then, we used RT-PCR and western blotting to prove the silencing of siRNAs against Runx2 and Smad4. Osteoblast terminal differentiation was determined by von kossa staining. And then we evaluated the effect of non-viral transduction of siRNAs against Runx2 and/or Smad4 on heterotopic ossification after Achilles tenotomy in rats. Ten weeks after the surgery, we used three-dimensional CT to determine the heterotopic ossification volume. Histological examinations and immunohistochemistry examinations showed the area of heterotopic ossification. The research design received approval from the Animal Care and Use Committee of Peking University and conformed to National Institutes of Health Guidelines.
Cell culture
Primary osteoblasts were isolated from the calvarias of 21-day fetal rats, which were obtained from Peking University Laboratory Animal Centre. 46 In brief, cells were obtained from the calvarias (the dura and periosteum removed) by five sequential digestions of 10 min at 37 1C in phosphatebuffered saline (PBS) containing 0.05% collagenase. Cells from the fourth and fifth digests were used in the study. The cells were suspended in Dulbecco's modified Eagle's medium (Gibco, Laboratories, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Cyclones, Logan, UT, USA), penicillin (100 units ml -1 ), and streptomycin (100 units ml -1 ) at 37 1C in a humidified atmosphere of 5% carbon dioxide and 95% air. 
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Small interference RNA synthesis and transfect ion
Six target sequences (Tables 2 and 3) for rat Runx2 and Smad4 messenger RNA were chosen according to Ambion's siRNA online design tool. The specificities of all sequences were confirmed by BLAST search. All siRNAs were synthesized using the silencer siRNA construction kit (Ambion, Austin, TX, USA) according to the manufacturer's protocol. The negative control (scrambled) siRNA was purchased from Ambion. Transfect ion of siRNA was performed by the siPORT Lipid (Ambion) according to the manufacturer's protocol. We synthesized three siRNAs against different target sites of Runx2, and another three siRNAs against different target sites of Smad4. The concentration of the siRNA preparation was assessed by measuring the absorbance of the siRNA sample at 260 nM with an ultraviolet spectrophotometer (BECKMAN DU-530, Pegasus Scientific Inc., Rockville, MD, USA). The degree of purification of the siRNA was assessed by gel electrophoresis on 2% agarose, with the appearance of a single band at 21 bp indicating a pure sample (data not shown). We then transfected siRNAs against Runx2, Smad4 and a scrambled control siRNA separately into primary osteoblastic cells by lipofection, 72 h later.
Non-virus small interference RNA plasmid construction
Construction of PB (cytomegalovirus-siRNA) was as follows: the siRNA templates were designed and Non-virus-mediated transfer of siRNAs T Xue et al synthesized according to Ambion's siRNA online design tool and inserted into the shuttle vector 1.0 cytomegalovirus at the XhoI and SpeI restriction enzyme sites. The siRNA cassette was then excised with AscI and inserted into the AscI site of pBac{3 Â P3-EGFPafm}. 47 Primary osteoblasts were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37 1C and 5% CO 2 . A total of 8 Â 10 5 cells were seeded into each well of a 6-well plate1 day before transfect ion. For each well, 2 mg circular PB (cytomegalovirus-siRNA) in the test group or 2 mg circular pcDNA4/HisA in the control group were transfected using LipofectAMINE 2000 according to standard protocols (Invitrogen, Carlsbad, CA, USA). These conditions enabled approximately 60% transduction of transgenes into osteoblastic cells (data not shown).
The PB vectors were provided by the Institute of Development Biology and Molecular Medicine at Fudan University.
Reverse transcription-PCR analysis
Total RNA was extracted from cultured cells using TRIzol Reagent (Invitrogen) after washing with PBS solution. Isolated RNA was reversely transcribed and then amplified using a commercial kit (Access RT-PCR system, Promega, Madison, WI, USA) according to the manufacturer's protocol. The specific primers are shown in Table 4 . The housekeeping gene b-act in was amplified as an internal control. Total RNAs (4 mg) were reversely transcribed for 45 min at 54 1C, and PCR amplification was then performed in a volume of 50 ml. PCR products were separated on 1% agarose gels and visualized by ethidium bromide staining.
Western blotting analysis
The harvested medium was collected on the day 14. Protein concentrations were measured with the BAC protein assay kit (Pierce Biotechnology Inc., Rockford, IL, USA) using bovine serum albumin as the standard. Proteins were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and electrotransferred to nitrocellulose membrane at 4 1C for 2 h. The blots were probed with anti-Runx2 and anti-Smad4 antibodies (Santa Cruz, CA, USA) at 1:500 dilutions overnight at 4 1C. After reaction with the secondary antibody, the proteins were detected by chemiluminescence according to manufacturer's recommendations (ECL, Amersham, Arlington Heights, IL, USA). B-actin was used as an internal control.
Matrix mineralization
To determinate extracellular matrix mineralization, on day 21 the cells were fixed for von kossa silver staining. Briefly, fixed cells were stained with 5% silver nitrate for 30 min under sunlight, fixed with sodium thiosulfate for 5 min, rinsed with distilled water, and mounted for inspection.
Animal experiments
All comparisons between treated and untreated limbs were made in the same animals so that animal-to-animal variations in the ability to form heterotopic ossification would not affect the results.
We evaluated the ability of non-viral transduction of siRNA against Runx2 to inhibit heterotopic ossification after Achilles tenotomy. Eight male immunocompetent rats (4 weeks old) underwent bilateral midpoint Achilles tenotomy with a posterior approach. The incision was routinely closed with an interrupted 4-0 silk suture. Twenty-four hours later, each rat was injected with 100 mg PB-Runx2-siRNA into the Achilles site and 100 mg pcDNA4/HisA into the contra lateral side. The surgeon was blinded with regard to which limb received treatment during the surgery. Non-virus-mediated transfer of siRNAs T Xue et al At 10 weeks after the surgery, the animals were scanned by CT on a Picker PQ 6000 scanner (United Medical Technologies Corp, Fort Myers, FL, USA). Axial images with a 1 mm collimation and 1 mm table increment were obtained with the standard algorithm with 130 kV, 100 mA, 2 s scan time and a 40 mm image size. Three-dimensional reconstruction and bone volumes were performed using a Voxel Q workstation (United Medical Technologies Corp). The Achilles tendons were removed and fixed in 10% neutral-buffered formalin, and then the ossified tissues were decalcified with decalcifying solution composed of 10% hydrochloric acid and 0.1% ethylenediaminetetraacetic acid. The samples were embedded in paraffin and sectioned. The slides were stained with HE. For immunohistochemistry, all tissue sections were depilated in xylol (2 Â 30 min). After rehydration in PBS, antigen unmasking was performed by incubating the slides for 15 min in trypsin (0.05% in PBS, PAA Laboratories GmbH, Pasching, Austria) at 37 1C. After washing with PBS, the activity of endogenous peroxidase was quenched with 3% hydrogen peroxide in PBS for 10 min at room temperature. The primary rabbit polyclonal antibody to osteocalcin (1:100 dilution; Santa Cruz) and nonspecific antibodies as a negative control were applied to tissue sections in a humidified chamber and incubated overnight at 4 1C. The slides were washed in PBS and incubated with a secondary biotinylated anti-rabbit antibody (1:100 dilutions, Dako, Dako Cytomation, Hamburg, Germany) for 90 min at room temperature. After washing in PBS, the presence of antibody-antigen complexes was visualized by incubating slides in Cardassian diaminobenzidine (Biocare Medical, American Medical Bio Care, Newport Beach, CA, USA) for 5 min at room temperature. Slides were rinsed for 5 min in water then counterstained with hematoxylin (Vector Laboratories Inc., Burlingame, CA, USA). Slides were mounted under cover slips with cytoseal XYL (RichardAllen Scientific, Kalamazoo, MI, USA). Negative controls included incubation of the contra lateral side with antiosteocalcin.
Meanwhile, we treated groups Smad4 and their coexpression similarly as group Runx2, except for that Smad4 and their co-expression replaced Runx2 for Smad4 and their co-expression, respectively.
